Fibrous and Fibrohistiocytic Neoplasms. An Update.

Dermatologic Clinics

Volumn 30, Issue 4, 2012, Pages 643-656

  Clarke, Loren E ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Atypical fibroxanthoma; CD10; Dermatofibrosarcoma protuberans (DFSP); Desmoid tumor (desmoid fibromatosis); Myxofibrosarcoma; Nerve sheath myxoma; Neurothekeoma; Solitary fibrous tumor

Indexed keywords

BETA CATENIN; CD34 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; IMATINIB; PLATELET DERIVED GROWTH FACTOR B; PROTEIN S 100;

CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COLLAGEN TYPE 1 ALPHA1 GENE; DERMATOFIBROSARCOMA PROTUBERANS; DESMOID TUMOR; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; FIBROSARCOMA; FIBROXANTHOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MYXOFIBROSARCOMA; NEUROTHEKEOMA; ONCOGENE; OVERALL SURVIVAL; PLATELET DERIVED GROWTH FACTOR B GENE; PREDICTION; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SOLITARY FIBROUS TUMOR;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BETA CATENIN; DERMATOFIBROSARCOMA; FIBROMATOSIS, ABDOMINAL; HISTIOCYTOMA, MALIGNANT FIBROUS; HUMANS; MYXOSARCOMA; NEPRILYSIN; NEUROTHEKEOMA; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PROGNOSIS; PYRIMIDINES; SKIN NEOPLASMS; SOLITARY FIBROUS TUMORS;

EID: 84866789466     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2012.06.005     Document Type: Review

References (45)

1. Angervall L., Kindblom L.G., Merck C. Myxofibrosarcoma. A study of 30 cases. Acta Pathol Microbiol Scand A 1977, 85(2):127-140.
2. Hollowood K., Fletcher C.D. Malignant fibrous histiocytoma: morphologic pattern or pathologic entity?. Semin Diagn Pathol 1995, 12(3):210-220.
3. Fletcher C.D. Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol 1992, 16(3):213-228.
4. Fletcher C.D. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 2006, 48(1):3-12.
5. Mentzel T., Calonje E., Wadden C., et al. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol 1996, 20(4):391-405.
6. Weedon D., Williamson R., Mirza B. CD10, a useful marker for atypical fibroxanthomas. Am J Dermatopathol 2005, 27(2):181.
7. de Feraudy S., Mar N., McCalmont T.H. Evaluation of CD10 and procollagen 1 expression in atypical fibroxanthoma and dermatofibroma. Am J Surg Pathol 2008, 32(8):1111-1122.
8. Hultgren T.L., DiMaio D.J. Immunohistochemical staining of CD10 in atypical fibroxanthomas. J Cutan Pathol 2007, 34(5):415-419.
9. Kanner W.A., Brill L.B., Patterson J.W., et al. CD10, p63 and CD99 expression in the differential diagnosis of atypical fibroxanthoma, spindle cell squamous cell carcinoma and desmoplastic melanoma. J Cutan Pathol 2010, 37(7):744-750.
10. Clarke L.E., Frauenhoffer E., Fox E., et al. CD10-positive myxofibrosarcomas: a pitfall in the differential diagnosis of atypical fibroxanthoma. J Cutan Pathol 2010, 37(7):737-743.
11. Bilalovic N., Sandstad B., Golouh R., et al. CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression. Mod Pathol 2004, 17(10):1251-1258.
12. Kanitakis J., Narvaez D., Claudy A. Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin. Melanoma Res 2002, 12(3):241-244.
13. Carrel S., Zografos L., Schreyer M., et al. Expression of CALLA/CD10 on human melanoma cells. Melanoma Res 1993, 3(5):319-323.
14. Wieland C.N., Dyck R., Weenig R.H., et al. The role of CD10 in distinguishing atypical fibroxanthoma from sarcomatoid (spindle cell) squamous cell carcinoma. J Cutan Pathol 2011, 38(11):884-888.
15. Fetsch J.F., Laskin W.B., Miettinen M. Nerve sheath myxoma: a clinicopathologic and immunohistochemical analysis of 57 morphologically distinctive, S-100 protein- and GFAP-positive, myxoid peripheral nerve sheath tumors with a predilection for the extremities and a high local recurrence rate. Am J Surg Pathol 2005, 29(12):1615-1624.
16. Fetsch J.F., Laskin W.B., Hallman J.R., et al. Neurothekeoma: an analysis of 178 tumors with detailed immunohistochemical data and long-term patient follow-up information. Am J Surg Pathol 2007, 31(7):1103-1114.
17. Sheth S., Li X., Binder S., et al. Differential gene expression profiles of neurothekeomas and nerve sheath myxomas by microarray analysis. Mod Pathol 2011, 24(3):343-354.
18. Smith K.J., Skelton H.G. Solitary fibrous tumor. Am J Dermatopathol 2001, 23(1):81-82.
19. Erdag G., Qureshi H.S., Patterson J.W., et al. Solitary fibrous tumors of the skin: a clinicopathologic study of 10 cases and review of the literature. J Cutan Pathol 2007, 34(11):844-850.
20. Soldano A.C., Meehan S.A. Cutaneous solitary fibrous tumor: a report of 2 cases and review of the literature. Am J Dermatopathol 2008, 30(1):54-58.
21. Wood L., Fountaine T.J., Rosamilia L., et al. Cutaneous CD34+ spindle cell neoplasms: histopathologic features distinguish spindle cell lipoma, solitary fibrous tumor, and dermatofibrosarcoma protuberans. Am J Dermatopathol 2010, 32(8):764-768.
22. Bhattacharya B., Dilworth H.P., Iacobuzio-Donahue C., et al. Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol 2005, 29(5):653-659.
23. Carlson J.W., Fletcher C.D. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology 2007, 51(4):509-514.
24. Stacchiotti S., Pedeutour F., Negri T., et al. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. Int J Cancer 2011, 129(7):1761-1772.
25. Erdem O., Wyatt A.J., Lin E., et al. Dermatofibrosarcoma protuberans treated with wide local excision and followed at a cancer hospital: prognostic significance of clinicopathologic variables. Am J Dermatopathol 2012, 34(1):24-34.
26. Hamada M., Hirakawa N., Fukuda T., et al. A progression to dermatofibrosarcoma protuberans with a fibrosarcomatous component: a special reference to the chromosomal aberrations. Pathol Res Pract 1999, 195(7):451-460.
27. Diaz-Cascajo C., Weyers W., Borrego L., et al. Dermatofibrosarcoma protuberans with fibrosarcomatous areas: a clinico-pathologic and immunohistochemic study in four cases. Am J Dermatopathol 1997, 19(6):562-567.
28. Goldblum J.R., Reith J.D., Weiss S.W. Sarcomas arising in dermatofibrosarcoma protuberans: a reappraisal of biologic behavior in eighteen cases treated by wide local excision with extended clinical follow up. Am J Surg Pathol 2000, 24(8):1125-1130.
29. Pedeutour F., Simon M.P., Minoletti F., et al. Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement. Cytogenet Cell Genet 1996, 72(2-3):171-174.
30. Pedeutour F., Simon M.P., Minoletti F., et al. Ring 22 chromosomes in dermatofibrosarcoma protuberans are low-level amplifiers of chromosome 17 and 22 sequences. Cancer Res 1995, 55(11):2400-2403.
31. Kikuchi K., Soma Y., Fujimoto M., et al. Dermatofibrosarcoma protuberans: increased growth response to platelet-derived growth factor BB in cell culture. Biochem Biophys Res Commun 1993, 196(1):409-415.
32. Macarenco R.S., Zamolyi R., Franco M.F., et al. Genomic gains of COL1A1-PDFGB occur in the histologic evolution of giant cell fibroblastoma into dermatofibrosarcoma protuberans. Genes Chromosomes Cancer 2008, 47(3):260-265.
33. Minoletti F., Miozzo M., Pedeutour F., et al. Involvement of chromosomes 17 and 22 in dermatofibrosarcoma protuberans. Genes Chromosomes Cancer 1995, 13(1):62-65.
34. Han A., Chen E.H., Niedt G., et al. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans. Arch Dermatol 2009, 145(7):792-796.
35. Handolias D., McArthur G.A. Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer. Future Oncol 2008, 4(2):211-217.
36. Johnson-Jahangir H., Ratner D. Advances in management of dermatofibrosarcoma protuberans. Dermatol Clin 2011, 29(2):191-200. viii.
37. Johnson-Jahangir H., Sherman W., Ratner D. Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses. J Natl Compr Canc Netw 2010, 8(8):881-885.
38. Labropoulos S.V., Fletcher J.A., Oliveira A.M., et al. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs 2005, 16(4):461-466.
39. Labropoulos S.V., Razis E.D. Imatinib in the treatment of dermatofibrosarcoma protuberans. Biologics 2007, 1(4):347-353.
40. Lemm D., Muegge L.O., Hoeffken K., et al. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans-a case report. Oral Maxillofac Surg 2008, 12(4):209-213.
41. Llombart B., Sanmartin O., Lopez-Guerrero J.A., et al. Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB) study with therapeutic implications. Histopathology 2009, 54(7):860-872.
42. Rutkowski P., Debiec-Rychter M., Nowecki Z., et al. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. J Eur Acad Dermatol Venereol 2011, 25(3):264-270.
43. Rutkowski P., Van Glabbeke M., Rankin C.J., et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010, 28(10):1772-1779.
44. Thomison J., McCarter M., McClain D., et al. Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate. J Cutan Pathol 2008, 35(11):1003-1006.
45. Kerob D., Porcher R., Verola O., et al. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res 2010, 16(12):3288-3295.